ELOX Eloxx Pharmaceuticals, Inc.
Executive Summary
Eloxx Pharmaceuticals filed Amendment No. 2 to its S-1 registration statement for a public offering of 2,730,000 shares of common stock and pre-funded warrants to purchase up to 2,770,000 shares of common stock at an assumed price of $10.00-$12.00 per share. The company estimates net proceeds of approximately $54.2 million, which it plans to use to fund its Phase 2b trial of exaluren in Alport syndrome (topline data mid-2027) and a Phase 2 trial in ADPKD (topline data mid-2028). The offering is contingent upon Nasdaq uplisting approval; the company currently trades on the OTC Pink Limited Market.
Key Financial Metrics
Actionable Insight
The offering is the key catalyst; its success determines whether Eloxx can fund its Phase 2b Alport syndrome and Phase 2 ADPKD trials. Monitor for pricing, Nasdaq approval, and trial initiation in Q3 2026. The reverse stock split and pending uplisting are critical structural events for share liquidity.
Key Facts
- Offering 2,730,000 shares of common stock and pre-funded warrants to purchase up to 2,770,000 shares of common stock at assumed $10.00-$12.00 per share.
- Estimated net proceeds of approximately $54.2 million, based on the midpoint of the price range.
- Plans to use $13.2 million for exaluren Phase 2b trial in Alport syndrome through topline data and $19.2 million for exaluren Phase 2 trial in ADPKD through completion.
- Company has a going concern qualification and an accumulated deficit of $304.3 million as of March 31, 2026.
- Offering is contingent upon Nasdaq Capital Market approval; common stock currently quoted on OTC Pink Limited Market.
- Net losses of $6.0 million (FY2025), $3.1 million (FY2024), and $3.8 million (Q1 2026).
- Cash and cash equivalents of $6.4 million as of March 31, 2026; pro forma cash of $60.6 million after offering.
Financial Impact
Estimated net proceeds of ~$54.2 million from the offering, intended to fund clinical trials through mid-2028.
Risk Factors
- Substantial doubt about going concern if offering fails; company does not have funds to commence planned Phase 2 trials without proceeds.
- Delisting risk from OTC Pink; Nasdaq uplisting is a condition of the offering and not guaranteed.
- Clinical risk: FSD has not been validated as a surrogate endpoint for FDA approval in Alport syndrome.
- Material weakness in internal controls over financial reporting has not been remediated.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-257750 |
| Document: d35071dex1060.htm | 0001193125-26-257750 |
| Document: d35071dexfilingfees.htm | 0001193125-26-257750 |
| Document: d35071dex231.htm | 0001193125-26-257750 |
| Document: 0001193125-26-257750-index-headers.html | 0001193125-26-257750 |
| Document: 0001193125-26-257750-index.html | 0001193125-26-257750 |
| Document: 0001193125-26-257750.txt | 0001193125-26-257750 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
2d ago
|
S-1/A
| — | awaiting T+5 | — | — |
|
Jun 1, 2026
5d ago
|
S-1/A
| — | awaiting T+5 | — | — |
|
Jun 1, 2026
5d ago
|
8-K
| — | awaiting T+5 | — | — |
|
May 7, 2026
4w ago
|
S-1
| $1.43 $1.93 | ▲ +34.51% | ▲ +34.30% | $6.20 (+333.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access